Personalis Stock Price, News & Analysis

Personalis (PSNL) reported strong Q3 2024 financial results with total revenue of $25.7 million, up 41% year-over-year. Biopharma revenue grew 96% to $15.7 million, while Enterprise revenue decreased 33% to $5.3 million. The company raised approximately $62.2 million through various financing activities, including transactions with Tempus AI and ATM program sales. Cash position stands at $143.7 million, extending runway into H1 2027. The company increased its full-year 2024 revenue guidance to $83-84 million, up from previous $79-81 million, despite reporting a net loss of $39.1 million for Q3.

Personalis, a leading company in advanced genomics for precision oncology, has announced its participation in the Stifel 2024 Healthcare Conference. The company's management team is scheduled to present on Tuesday, November 19, at 10:55 a.m. Eastern Time. The presentation will take place at the Lotte New York Palace Hotel in New York, NY.

Personalis (Nasdaq: PSNL) has scheduled its third quarter 2024 financial results announcement for Wednesday, November 6, 2024. The company will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day to discuss the results and recent highlights. Investors can join via phone (877-451-6152 domestic, 201-389-0879 international) or through the company's website. A replay will be available and archived online after the call.

Personalis, Inc. (Nasdaq: PSNL) presented compelling data at ESMO 2024 for its NeXT Personal® MRD test. Two studies showcased the test's effectiveness in lung cancer monitoring and immunotherapy response assessment. The TRACERx study, analyzing over 400 NSCLC patients, demonstrated strong detection rates for residual lung cancer post-surgery, with 42% of detections in the ultrasensitive range. The test showed high sensitivity in detecting early-stage recurrence months ahead of imaging. Another study by VHIO, involving 200+ late-stage cancer patients on immunotherapy, revealed that significant ctDNA level decreases correlated with longer overall survival. These findings underscore the importance of ultrasensitive MRD testing in cancer management and therapy response monitoring.

Personalis, a leader in advanced genomics for precision oncology, has announced its participation in two upcoming investor conferences. The company's management team will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, where they will give a presentation at 4:50 pm Eastern Time at the Marriott Marquis in New York. Additionally, Personalis will attend the Lake Street 8th Annual Best Ideas Growth (BIG) Conference on September 12, 2024, at the Yale Club in New York.

These conferences provide Personalis with opportunities to showcase their advancements in genomics and precision oncology to potential investors and industry professionals. The company's participation in such events demonstrates its commitment to engaging with the investment community and sharing its vision for the future of personalized cancer care.

Personalis (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, has announced the granting of a non-qualified stock option to its new Executive Director of Market Access & Reimbursement. The Compensation Committee of the Board of Directors approved this grant on August 15, 2024, under the company's 2020 Inducement Plan.

The stock option allows for the purchase of 75,000 shares of Personalis' common stock at an exercise price of $5.07 per share, equal to the closing price on the grant date. The option vests over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years, subject to continued service.

Personalis (PSNL) and Tempus (TEM) have expanded their commercial collaboration, with Tempus investing $36 million in Personalis. This investment includes exercising warrants to purchase 9.2 million shares at an average price of $2.00 and buying an additional 3.5 million shares at $5.07 each. The expansion follows strong demand for their ultra-sensitive MRD testing in breast and lung cancers, as well as immunotherapy monitoring across solid tumors.

Key points of the expanded collaboration include:

• Tempus accelerating commercialization efforts over the first two years
• Personalis increasing the quantity of patient samples it will accept
• Tempus becoming the exclusive commercial partner for Personalis' MRD product
• Tempus owning approximately 19.3% of Personalis' outstanding common stock after the transaction

Personalis, Inc. (Nasdaq: PSNL) reported strong financial results for Q2 2024, with total revenue increasing 35% year-over-year to $22.6 million. The growth was primarily driven by a 117% increase in revenue from pharma testing and services, reaching $13.2 million. Enterprise customer revenue grew 8% to $8.0 million. The company highlighted clinical performance of NeXT Personal® at ASCO, demonstrating early cancer recurrence detection and therapy response prediction.

Personalis delivered 561 molecular tests in Q2, a 66% increase from the previous quarter. The company also announced cross-license agreements and settled an IP lawsuit. Despite revenue growth, Personalis reported a net loss of $12.8 million, a 47% improvement year-over-year. The company raised its full-year 2024 revenue guidance to $79.0-$81.0 million and expects Q3 2024 revenue between $21.0-$22.0 million.

Personalis, a leader in advanced genomics for cancer, has announced its participation in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The event is scheduled for Tuesday, August 13, 2024, and Personalis' management team will be attending virtually. This conference provides an opportunity for Personalis (Nasdaq: PSNL) to showcase its expertise in cancer genomics and engage with industry professionals.

The Needham conference is a significant platform for companies in the medical technology and diagnostics sectors to present their innovations and connect with potential investors and partners. Personalis' participation underscores its commitment to advancing cancer genomics and maintaining its position as a key player in the field.